Wayne Markowitz - 07 May 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: GM & SVP, Surgical
Issuer ticker: EW
Reported as of: 07 May 2025
Net transaction value: -$42,597
SEC form: 4
Accepted by SEC: 09 May 2025, 19:34:16 UTC
Prior SEC filing: 06 Dec 2024
Next SEC filing: 15 Sep 2025
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Wayne Markowitz filed Form 4 for Edwards Lifesciences Corp (EW) on 09 May 2025.

Key facts

This page summarizes Wayne Markowitz's Form 4 filing for Edwards Lifesciences Corp (EW).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 May 2025, 19:34.

Change

Previous filing in this sequence was filed on 06 Dec 2024.
Current net transaction value: -$42,597.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001991414 Primary reporting owner

Markowitz Wayne

Relationship: GM & SVP, Surgical
Address: ONE EDWARDS WAY, IRVINE
Signature: Linda J. Park, Attorney-in-Fact
Signature date: 09 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Sale

Transaction value: $20,121
Shares: -268
Change %: -2.8%
Price: $75.08
Shares after: 9,299
Date: 07 May 2025
Ownership: Direct

EW transaction

Common Stock

Tax liability

Transaction value: $22,476
Shares: -300
Change %: -3.2%
Price: $74.92
Shares after: 8,999
Date: 07 May 2025
Ownership: Direct

EW transaction

Common Stock

Award

Transaction value: $0
Shares: +3,350
Change %: +37%
Price: $0.000000
Shares after: 12,349
Date: 08 May 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Award

Transaction value: $0
Shares: +17,100
Change %
Price: $0.000000
Shares after: 17,100
Date: 08 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,100
Exercise price: $74.63
Footnotes: F2

EW transaction Derivative

Performance Rights

Award

Transaction value: $0
Shares: +3,350
Change %
Price: $0.000000
Shares after: 3,350
Date: 08 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,350
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Footnote F2

These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Footnote F3

Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.